Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia BackgroundSchizophrenia is a chronic debilitating disease. The pathogenesis and treatment may be associated with inflammatory cytokines. There are few studies focusing on the prediction of cytokines in response to antipsychotics.AimTo investigate whether cytokines would predict response to antipsychotics.MethodsCross-sectional and natural observational cohort studies were applied to:(1) compare the baseline levels of serum IL-1β, TNF-α and MCP-1 between schizophrenia (n=64) and healthy controls (n=53); (2) To investigate the impact of baseline cytokines to psychopathology following olanzapine and risperidone monotherapy.Results(1) Baseline MCP-1 level of patients with schizophrenia was significantly higher than healthy controls (t=2.62, p=0.010), while no significance was found in IL-1β (t=1.43, p=0.154) and TNF-α (t=0.79, p=0.434); (2) Pretreatment level of MCP-1 significantly correlated with PANSS-G reduction following 4 weeks’ of risperidone monotherapy (r =-0.658; p<0.001) but not olanzapine monotherapy (r =-0.031; p=0.855); (3) Further stepwise multiple linear regression analysis indicated that higher MCP-1 level prior to treatment was a significant predictor of less PANSS-G reduction in schizophrenia patients following risperidone monotherapy (adjusted R2= 0.409, β = -0.658, p <0.001), but not in the olanzapine group.ConclusionMCP-1 may play a role in the pathogenesis of schizophrenia. Pretreatment level of MCP-1 may serve as a biomarker indicating response to risperidone treatment. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Shanghai Archives of Psychiatry Pubmed Central

Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia

,; ,; ,; ,; ,; ,; ,; ,
Shanghai Archives of Psychiatry , Volume 29 (5) – Oct 25, 2017
8 pages

Loading next page...
 
/lp/pubmed-central/pretreatment-serum-mcp-1-level-predicts-response-to-risperidone-in-qr7L3t0P5c

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Pubmed Central
Copyright
© Shanghai Municipal Bureau of Publishing
ISSN
1002-0829
DOI
10.11919/j.issn.1002-0829.217093
Publisher site
See Article on Publisher Site

Abstract

BackgroundSchizophrenia is a chronic debilitating disease. The pathogenesis and treatment may be associated with inflammatory cytokines. There are few studies focusing on the prediction of cytokines in response to antipsychotics.AimTo investigate whether cytokines would predict response to antipsychotics.MethodsCross-sectional and natural observational cohort studies were applied to:(1) compare the baseline levels of serum IL-1β, TNF-α and MCP-1 between schizophrenia (n=64) and healthy controls (n=53); (2) To investigate the impact of baseline cytokines to psychopathology following olanzapine and risperidone monotherapy.Results(1) Baseline MCP-1 level of patients with schizophrenia was significantly higher than healthy controls (t=2.62, p=0.010), while no significance was found in IL-1β (t=1.43, p=0.154) and TNF-α (t=0.79, p=0.434); (2) Pretreatment level of MCP-1 significantly correlated with PANSS-G reduction following 4 weeks’ of risperidone monotherapy (r =-0.658; p<0.001) but not olanzapine monotherapy (r =-0.031; p=0.855); (3) Further stepwise multiple linear regression analysis indicated that higher MCP-1 level prior to treatment was a significant predictor of less PANSS-G reduction in schizophrenia patients following risperidone monotherapy (adjusted R2= 0.409, β = -0.658, p <0.001), but not in the olanzapine group.ConclusionMCP-1 may play a role in the pathogenesis of schizophrenia. Pretreatment level of MCP-1 may serve as a biomarker indicating response to risperidone treatment.

Journal

Shanghai Archives of PsychiatryPubmed Central

Published: Oct 25, 2017

There are no references for this article.